Noonan Syndrome
|
1.000 |
CausalMutation
|
disease |
CLINVAR |
14-3-3 antagonizes Ras-mediated Raf-1 recruitment to the plasma membrane to maintain signaling fidelity.
|
12077328 |
2002 |
Noonan Syndrome
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Noonan syndrome (NS) is an autosomal dominant disorder caused by mutations in PTPN11, KRAS, SOS1, and RAF1.
|
19953625 |
2010 |
Noonan Syndrome
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Noonan Syndrome (NS) is an autosomal dominant condition characterized by short stature, facial dysmorphisms, and congenital heart defects, and is caused by mutations in either PTPN11, KRAS, NRAS, SHOC2, RAF1, or SOS1.
|
20461756 |
2010 |
Noonan Syndrome
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Noonan syndrome associated with both a new Jnk-activating familial SOS1 and a de novo RAF1 mutations.
|
20683980 |
2010 |
Noonan Syndrome
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
RAF1 mutations are most frequent in NS with HCM, while PTPN11 mutations are also well known.
|
26286251 |
2015 |
Noonan Syndrome
|
1.000 |
GeneticVariation
|
disease |
CLINVAR |
A GaN bulk crystal with improved structural quality grown by the ammonothermal method.
|
17603489 |
2007 |
Noonan Syndrome
|
1.000 |
CausalMutation
|
disease |
CLINVAR |
A Novel Noonan Syndrome RAF1 Mutation: Lethal Course in a Preterm Infant.
|
26266034 |
2015 |
Noonan Syndrome
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Anthropometric measurements (mean of 4.3 measurements per patient) were obtained in a mixed cross-sectional and longitudinal mode from 127 NS and 10 NLS patients with mutations identified in PTPN11 (n = 90), SOS1 (n = 14), RAF1 (n = 10), KRAS (n = 8), BRAF (n = 11), and SHOC2 (n = 4) genes.
|
22887833 |
2012 |
Noonan Syndrome
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Atypical forms of NSML could be associated with NS with RAF1 or NRAS mutations.
|
30417923 |
2019 |
Noonan Syndrome
|
1.000 |
Biomarker
|
disease |
CLINGEN |
Cells transfected with constructs containing Noonan syndrome-associated RAF1 mutations showed increased in vitro kinase and ERK activation, and zebrafish embryos with morpholino knockdown of raf1 demonstrated the need for raf1 for the development of normal myocardial structure and function.
|
17603482 |
2007 |
Noonan Syndrome
|
1.000 |
Biomarker
|
disease |
CTD_human |
Cells transfected with constructs containing Noonan syndrome-associated RAF1 mutations showed increased in vitro kinase and ERK activation, and zebrafish embryos with morpholino knockdown of raf1 demonstrated the need for raf1 for the development of normal myocardial structure and function.
|
17603482 |
2007 |
Noonan Syndrome
|
1.000 |
GeneticVariation
|
disease |
LHGDN |
Cells transfected with constructs containing Noonan syndrome-associated RAF1 mutations showed increased in vitro kinase and ERK activation, and zebrafish embryos with morpholino knockdown of raf1 demonstrated the need for raf1 for the development of normal myocardial structure and function.
|
17603482 |
2007 |
Noonan Syndrome
|
1.000 |
GeneticVariation
|
disease |
CLINVAR |
Cells transfected with constructs containing Noonan syndrome-associated RAF1 mutations showed increased in vitro kinase and ERK activation, and zebrafish embryos with morpholino knockdown of raf1 demonstrated the need for raf1 for the development of normal myocardial structure and function.
|
17603482 |
2007 |
Noonan Syndrome
|
1.000 |
CausalMutation
|
disease |
CLINVAR |
Cells transfected with constructs containing Noonan syndrome-associated RAF1 mutations showed increased in vitro kinase and ERK activation, and zebrafish embryos with morpholino knockdown of raf1 demonstrated the need for raf1 for the development of normal myocardial structure and function.
|
17603482 |
2007 |
Noonan Syndrome
|
1.000 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Cells transfected with constructs containing Noonan syndrome-associated RAF1 mutations showed increased in vitro kinase and ERK activation, and zebrafish embryos with morpholino knockdown of raf1 demonstrated the need for raf1 for the development of normal myocardial structure and function.
|
17603482 |
2007 |
Noonan Syndrome
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Cellular interplay via cytokine hierarchy causes pathological cardiac hypertrophy in RAF1-mutant Noonan syndrome.
|
28548091 |
2017 |
Noonan Syndrome
|
1.000 |
CausalMutation
|
disease |
CLINVAR |
ClinGen's RASopathy Expert Panel consensus methods for variant interpretation.
|
29493581 |
2018 |
Noonan Syndrome
|
1.000 |
GeneticVariation
|
disease |
CLINVAR |
Common variants in WFS1 confer risk of type 2 diabetes.
|
17603484 |
2007 |
Noonan Syndrome
|
1.000 |
Biomarker
|
disease |
CLINGEN |
Cyclosporine attenuates cardiomyocyte hypertrophy induced by RAF1 mutants in Noonan and LEOPARD syndromes.
|
21440552 |
2011 |
Noonan Syndrome
|
1.000 |
GeneticVariation
|
disease |
CLINVAR |
Downgrading of arts-centered education in state schools.
|
1760348 |
1992 |
Noonan Syndrome
|
1.000 |
CausalMutation
|
disease |
CLINVAR |
External ear anomalies and hearing impairment in Noonan Syndrome.
|
25862627 |
2015 |
Noonan Syndrome
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Gain-of-function mutations in the PTPN11, KRAS, SOS1, and RAF1 genes that are components of the RAS/MEPK signaling pathway are identified in about 70-85% of individuals with Noonan syndrome.
|
18348260 |
2008 |
Noonan Syndrome
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Gene-related Chinese NS facial features were described using artificial intelligence (AI).NGS identified pathogenic variants in 103 Chinese patients in eight NS-related genes: PTPN11 (48.5%), SOS1 (12.6%), SHOC2 (11.7%), KRAS (9.71%), RAF1 (7.77%), RIT1 (6.8%), CBL (0.97%), NRAS (0.97%), and LZTR1 (0.97%).
|
31219622 |
2019 |
Noonan Syndrome
|
1.000 |
Biomarker
|
disease |
BEFREE |
Germline mutations in genes encoding small GTPases of the RAS family (KRAS and NRAS), modulators of RAS function (PTPN11, SOS1 and SHOC2) or downstream signal transducers (RAF1) are causative for NS.
|
20673819 |
2011 |
Noonan Syndrome
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Heterozygous germline mutations in CRAF result in Noonan syndrome, which is characterized by neurocognitive impairment that may involve hippocampal physiology.
|
29590115 |
2018 |